← Leaderboards
Julie L Sutcliffe
University Of California Davis
$12,858,724
Attributed
$14,366,365
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2005–24$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$14,366,365 · 10
By mechanism
R01$5,718,766 · 4
RC4$3,519,967 · 1
U01$3,174,336 · 1
S10$872,940 · 2
R33$747,537 · 1
R21$332,819 · 1
Top collaborators
- Kimberly A. Kelly3 shared
- Cameron Carl Foster2 shared
Research focus
Positron-Emission TomographyImagePeptidesIn VivoMalignant NeoplasmsAffinityMolecular ImagingNeoplasm MetastasisPatient-Focused OutcomesBaseBindingSurvival RateNonhuman PrimateIntegrinsImaging AgentOperative Surgical ProceduresReceptorResourcesMolecular TargetAdultDrug KineticsCellsCell Surface ReceptorsMouse Model
Grant awards (24)
A novel molecularly targeted theranostic approach via the alphavbeta6 integrin for the detection and treatment of metastatic cancers$634,742
R01 · FY2024 · CA · contact PI
Integrated system for PET radiotracer synthesis$375,665
S10 · FY2024 · OD · contact PI
A novel molecularly targeted theranostic approach via the alphavbeta6 integrin for the detection and treatment of metastatic cancers$664,690
R01 · FY2023 · CA · contact PI
Peptide-based targeted molecular imaging for early detection in pancreatic cancer$629,109
U01 · FY2021 · CA · contact PI
Peptide-based targeted molecular imaging for early detection in pancreatic cancer$632,421
U01 · FY2020 · CA · contact PI
Peptide-based targeted molecular imaging for early detection in pancreatic cancer$615,523
U01 · FY2019 · CA · contact PI
Targeted Molecular Imaging of Plectin-1; Bench to bedside and back again$573,198
R01 · FY2019 · CA · contact PI
avb6-directed molecular imaging and therapy$487,668
R01 · FY2019 · CA · contact PI
First in human study with 18F-avb6-targeting peptide$173,311
R01 · FY2019 · CA · contact PI
Peptide-based targeted molecular imaging for early detection in pancreatic cancer$646,908
U01 · FY2018 · CA · contact PI
Targeted Molecular Imaging of Plectin-1; Bench to bedside and back again$617,985
R01 · FY2018 · CA · contact PI
avb6-directed molecular imaging and therapy$488,662
R01 · FY2018 · CA · contact PI
First in human study with 18F-avb6-targeting peptide$249,601
R01 · FY2018 · CA · contact PI
Peptide-based targeted molecular imaging for early detection in pancreatic cancer$650,375
U01 · FY2017 · CA · contact PI
Targeted Molecular Imaging of Plectin-1; Bench to bedside and back again$524,668
R01 · FY2017 · CA · contact PI
avb6-directed molecular imaging and therapy$488,662
R01 · FY2017 · CA · contact PI
First in human study with 18F-avb6-targeting peptide$354,083
R01 · FY2017 · CA · contact PI
avb6-directed molecular imaging and therapy$461,496
R01 · FY2016 · CA · contact PI
High throughput design, synthesis and in vivo evaluation of targeted molecular im$3,519,967
RC4 · FY2010 · EB · contact PI
An integrated radiopharmaceutical synthesis system$497,275
S10 · FY2008 · RR · contact PI
Targeting of alpha v beta 6 integrin in oral cancer$414,105
R33 · FY2007 · CA · contact PI
Targeting of alpha v beta 6 integrin in oral cancer$333,432
R33 · FY2006 · CA · contact PI
Targeting of alpha v beta 6 integrin in oral cancer$169,685
R21 · FY2005 · CA
Targeting of alpha v beta 6 integrin in oral cancer$163,134
R21 · FY2004 · CA